Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
By E. Gonzalez-Lopez, M. Gallego-Delgado, Gonzalo Guzzo-Merello, F. J. de Haro-del Moral, M. Cobo-Marcos, C. Robles, B. Bornstein, C. Salas, E. Lara-Pezzi, L. Alonso-Pulpón and 1 more. European Heart Journal, 2015
1,041 citations recorded by the source corpus.
Subfields: Molecular Biology, Nephrology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/2045439104f816780607f20f81e88e282028b4dd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Genotype and Phenotype of Transthyretin Cardiac Amyloidosis in the United States: The Transthyretin Amyloid Outcome Survey (THAOS) (2016, positive): “ATTR cardiac amyloidosis is an underappreciated and often underdiagnosed cause of heart failure in the setting of a preserved ejection fraction (HFpEF) (19) with TTR deposits seen in up to 30% of older adults with HFpEF who undergo autopsy (20).”
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy (2018, neutral): “Pooled tafamidis Placebo 264 (0) 177 (0) 259 (5) 173 (4) 252 (12) 171 (6) 244 (20) 163 (14) 235 (29) 161 (16) 222 (42) 150 (27) 216 (48) 141 (36) 209 (55) 131 (46) 200 (64) 118 (59) 193 (71) 113 (64) 3 21 24 27 30”
- Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. (2016, background): “A recent series of HFpEF patients over the age of 60 years with left ventricular wall thicknesses >12 mm demonstrated a positive DPD scan consistent with a presumptive diagnosis of ATTRwt in 13%, without a sex difference (17).”
- Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (2017, methodology): “In Europe, 99mTc-DPD cardiac imaging has proven to be an effective screening tool for ATTR-CA, both among patients undergoing TAVR and HFpEF.25,27 Screening for ATTR-CA may identify ATTR-CA early in the setting of severe AS and/or HFpEF when emerging therapies may have greater benefit.”